scispace - formally typeset
G

Gerold Meinhardt

Researcher at Bayer HealthCare Pharmaceuticals

Publications -  65
Citations -  7918

Gerold Meinhardt is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 21, co-authored 61 publications receiving 5771 citations. Previous affiliations of Gerold Meinhardt include Bayer Corporation & Schering AG.

Papers
More filters
Journal ArticleDOI

Breast cancer, early stage

Tony Mok, +521 more
- 01 Sep 2012 - 
TL;DR: Post-hoc analyses of efficacy outcomes in MISSION suggest that advanced NSCLC patients with EGFR mutations may derive a survival benefit from receiving 3rd/4th line sorafenib, and these results must be interpreted with caution due to the small, non-representative nature of the genetic biomarker subpopulation analyzed in this trial.
Journal ArticleDOI

Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE).

TL;DR: The phase II SPACE study is being conducted in North America, Europe, and the Asia-Pacific region to evaluate the efficacy and safety of TACE plus doxorubicin-eluting beads plus either SOR or PL in patients with intermediate-stage HCC.
Journal ArticleDOI

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

TL;DR: Assessment of the activated vessel density may allow the stratification of patients recruited in randomised trials with VEGFR-targeting anti-angiogenic agents, unmasking their therapeutic potential and enabling their introduction in the clinical practice for the benefit of specific patient subgroups, at the same time reducing the cost of therapy.